Drug Search Results
More Filters [+]

Molgramostim

Alternative Names: molgramostim
Latest Update: 2024-12-18
Latest Update Note: News Article

Product Description

Mechanisms of Action: Immunostimulant

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Chile | China | Germany | Ireland | Italy | New Zealand | Pakistan | Peru | Portugal | Russia | Slovenia | Sweden | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Savara
Company Location: AUSTIN TX 78746
Company CEO: Matthew Pauls
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Molgramostim

Countries in Clinic: Australia, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Japan, Korea, Netherlands, Poland, Portugal, Romania, Spain, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Pulmonary Alveolar Proteinosis

Phase 2: Leg Ulcer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

aPAP

P3

Not yet recruiting

Pulmonary Alveolar Proteinosis

2027-01-01

72%

SAV00605

P3

Unknown Status

Pulmonary Alveolar Proteinosis

2026-12-31

jRCT2051210036

P3

Recruiting

Pulmonary Alveolar Proteinosis

2024-12-31

IMPALA-2

P3

Active, not recruiting

Pulmonary Alveolar Proteinosis

2023-11-30

Recent News Events